Bloomage BioTechnology (688363) Q3 2025 earnings summary

Executive summary

• Net profit attributable to shareholders in Q3 reached RMB 31.53 million, up 55.63% year-over-year, with revenue at RMB 902.71 million, down 15.16% year-over-year, marking a continued profit recovery trend and improved operational quality.

• Management implemented systematic adjustments in business philosophy, direction, and organizational structure, leading to significant improvements in efficiency and profitability.

• Core businesses—raw materials and medical terminal—accounted for about 60% of total revenue and maintained stable growth.

Financial highlights

• Q3 revenue: RMB 902.71 million, down 15.16% year-over-year; YTD revenue: RMB 3.16 billion, down 18.36% year-over-year.

• Q3 net profit attributable to shareholders: RMB 31.53 million, up 55.63% year-over-year; YTD: RMB 252.38 million, down 30.29% year-over-year.

• Q3 operating cash flow: RMB 90.43 million, up 858.55% year-over-year; YTD: RMB 308.76 million, up 12.66% year-over-year.

• Basic and diluted EPS for Q3: RMB 0.07, up 75% year-over-year; YTD: RMB 0.52, down 30.67% year-over-year.

• Gross margin and core profitability metrics improved sequentially.

Outlook and guidance

• Management expects continued improvement in profitability and operational quality, driven by business model optimization and focus on core segments.

• Strategic focus on anti-aging, integrating pharmaceuticals, medical aesthetics, nutrition, and skin science for synergistic growth.